Adial Pharmaceuticals (ADIL) Invested Capital (2022 - 2024)
Adial Pharmaceuticals' Invested Capital history spans 3 years, with the latest figure at $5.9 million for Q3 2024.
- For Q3 2024, Invested Capital rose 151.52% year-over-year to $5.9 million; the TTM value through Sep 2024 reached $5.9 million, up 151.52%, while the annual FY2023 figure was $4.1 million, 8.36% up from the prior year.
- Invested Capital for Q3 2024 was $5.9 million at Adial Pharmaceuticals, up from $4.3 million in the prior quarter.
- Across five years, Invested Capital topped out at $11.0 million in Q1 2022 and bottomed at $1.4 million in Q1 2023.
- The 3-year median for Invested Capital is $4.3 million (2024), against an average of $5.1 million.
- The largest annual shift saw Invested Capital plummeted 86.85% in 2023 before it skyrocketed 325.16% in 2024.
- A 3-year view of Invested Capital shows it stood at $3.8 million in 2022, then rose by 8.36% to $4.1 million in 2023, then surged by 44.08% to $5.9 million in 2024.
- Per Business Quant, the three most recent readings for ADIL's Invested Capital are $5.9 million (Q3 2024), $4.3 million (Q2 2024), and $6.1 million (Q1 2024).